Abstract
Methicillin-resistant/susceptible Staphylococcus aureus (MRSA/MSSA) and Enterococcus faecalis strains are often found in community- and hospital-acquired infections. The single use of conventional antibiotics hardly completely kills the bacterial cells of interest, especially in the form of biofilms. Thus, drug repurposing and antimicrobial combination are promising ways to solve this problem. Antimicrobial susceptibility assays against cocci in a suspension and in a biofilm mode of growth were performed with broth microdilution methods. Checkerboard assays and the cutaneous mouse infection model were used to examine the activity of auranofin and conventional antibiotics alone and in combination. In the present study, auranofin possesses potent antimicrobial activities against both planktonic cells and biofilms with minimum inhibitory concentrations ranging 0.125-0.5 mg/L. Auranofin in combination with linezolid or fosfomycin showed synergistic antimicrobial activities against S. aureus MSSA and MRSA both in vitro and in vivo. Similarly, auranofin also behaved synergistic effect with chloramphenicol against E. faecalis. Additionally, auranofin improved the antibiofilm efficacy of chloramphenicol and linezolid, even on the biofilms grown on a catheter surface. Though, S. epidermidis showed significant susceptibility to AF treatment, no synergistic antimicrobial effects were observed with antibiotics we tested. In all, the use of a combination of auranofin with linezolid, fosfomycin, and chloramphenicol can provide a synergistic microbicidal effect in vitro and in vivo, which rapidly enhances antimicrobial activity and may help prevent or delay the emergence of resistance.
Introduction
The rise of antibiotic resistance, particularly in Gram-positive cocci like Methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, represents a global health crisis. These pathogens are notorious for forming biofilms—complex, sticky communities of cells that adhere to surfaces such as medical catheters and host tissues. Biofilms act as a physical and metabolic shield, rendering bacteria up to 1,000 times more resistant to antibiotics than their free-floating (planktonic) counterparts. Given the slow and costly nature of new antibiotic development, drug repurposing and combination therapy offer a faster, more efficient strategy to enhance the existing antimicrobial arsenal. This study investigates Auranofin (AF), an FDA-approved drug for rheumatoid arthritis, as a potential synergistic agent against these resilient pathogens.
Methods
The researchers evaluated the efficacy of AF alone and in combination with various antibiotics through several methods:
- Antimicrobial Susceptibility Testing: Determined Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) using standard broth microdilution.
- Checkerboard Assays: Calculated the Fractional Inhibitory Concentration Index (FICI) to identify synergistic (FICI ≤ 0.5), additive, or antagonistic interactions.
- Biofilm Assays: Assessed preformed biofilms using Crystal Violet staining (biomass), XTT assays (metabolic activity), and direct live-cell counts.
- In Vivo Modeling: Tested treatment effectiveness in a cutaneous mouse abscess model to simulate high-density skin infections.
- Catheter Model: Evaluated the ability of drug combinations to clear biofilms from medical catheter surfaces.
Key Insights
Targeting Redox Homeostasis
Auranofin's primary mechanism involves inhibiting thioredoxin reductase (TrxR), an enzyme critical for maintaining bacterial redox balance. By disrupting this essential "housekeeping" system, AF likely weakens the bacteria, increasing their susceptibility to the primary attack of conventional antibiotics.
Pathogen-Specific Synergy
Synergy was found to be pathogen-specific. While AF combined effectively with Linezolid (LZD) or Fosfomycin (FOF) for S. aureus, and with Chloramphenicol (CHL) for E. faecalis, no synergy was observed for S. epidermidis despite its high susceptibility to AF alone. This suggests that synergistic mechanisms depend on specific metabolic pathways unique to each target species.
Biofilm Penetration and Eradication
A critical finding was the combination's ability to significantly lower the Minimum Biofilm Eradication Concentration (MBEC). AF effectively "unlocked" the biofilm structure, allowing antibiotics to penetrate and kill the encased cells.
Key Results
- Potency: AF alone demonstrated potent activity against planktonic cells with MICs ranging from 0.125 to 0.5 mg/L.
- Synergy in S. aureus: The AF+LZD combination reduced the MIC of LZD from 4 mg/L to 1 mg/L (FICI = 0.375). In biofilms, this combination resulted in a >8-fold decrease in the MBEC50 for LZD.
- Synergy in E. faecalis: Similar potent effects were observed for E. faecalis when AF was combined with chloramphenicol.
- In Vivo Success: In the mouse abscess model, the AF+LZD combination achieved a 4.51-log10 reduction in bacterial load compared to controls. Furthermore, the therapy achieved nearly a 5-log reduction in bacteria on catheter surfaces for S. aureus.
Limitations and Future Directions
While promising, the study notes that the lack of synergy in S. epidermidis remains unexplained, requiring further genomic or metabolic investigation. Additionally, while TrxR is a known target, the precise molecular interplay between AF and specific antibiotics like protein-synthesis inhibitors needs further mapping. Long-term studies are also necessary to confirm if this combination therapy effectively delays the emergence of resistance in clinical settings.
Summary updated